While drugmakers Novo Nordisk and Eli Lilly assert that shortages of popular weight loss and diabetes medications Wegovy, Ozempic, Mounjaro and Zepbound are easing, many patients continue to face challenges accessing the drugs, NPR reported Sept. 6.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
